- CEO
- Xiang Yun Qian
- Full Time Employees
- 540
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Changshu China
- IPO Date
- Mar 29, 2022
- Business
- Suzhou Fushilai Pharmaceutical Co., Ltd. is a China-based pharmaceutical and nutritional ingredient manufacturing company primarily engaged in the research, development, production, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and dietary supplement raw materials. Founded in 2000 and headquartered in Changshu, Jiangsu Province, China, the company operates across key specialized chemical and health sectors, supplying global pharmaceutical manufacturers, dietary supplement brand owners, food and beverage producers, and cosmetics formulators.
The company's core product offerings comprise: the Thioctic Acid series, including alpha-lipoic acid, R-alpha-lipoic acid, sodium R-lipoate, tromethamine lipoate, dihydrolipoic acid, and 6,8-dichlorooctanoic acid ethyl ester, which are widely utilized as antioxidants and active components for diabetic peripheral neuropathy therapeutics, nutritional supplements, and skin health products; the Carnitine series, featuring L-carnitine base, L-carnitine tartrate, L-carnitine fumarate, acetyl-L-carnitine hydrochloride, and propionyl-L-carnitine hydrochloride, applied in infant nutrition, sports nutrition, medical foods, and cardiovascular health formulations; phosphatidylserine and other specialty nutritional bio-compounds; and custom pharmaceutical intermediates and fine chemicals for cardiovascular, metabolic, and antiviral indications. In addition, the company provides Contract Development and Manufacturing Organization (CDMO) and custom synthesis services tailored to customer specifications across laboratory, pilot, and commercial scales. Geographically, the company maintains extensive market coverage across domestic China and exports to major international regions, including North America, Europe, Japan, South Korea, India, and Southeast Asia.
In recent developments, Suzhou Fushilai Pharmaceutical Co., Ltd. has accelerated its strategic transition into advanced CDMO services and high-barrier chiral pharmaceutical technologies. The company has expanded its modern cGMP-compliant manufacturing facilities, integrating automated synthesis units, continuous flow processing, and micro-reaction systems to scale production efficiency and environmental sustainability. To diversify its portfolio beyond bulk ingredients, the company has increased research and development investment in enzymatic biocatalysis and green chemistry platforms for high-purity chiral drug intermediates. Additionally, the company has strengthened its global regulatory compliance through expanded international drug master file (DMF) registrations and quality certifications, while establishing deepened commercial supply partnerships with international healthcare conglomerates.